Bayer joins growing US sector for HF (heart failure) blood test
This article was originally published in Clinica
Executive Summary
Bayer Diagnostics looks set to loosen the grip held by Biosite and Roche Diagnostics on the US market for heart failure (HF) blood tests based on BNP (B-type natriuretic peptide), after gaining FDA approval for its fully automated version of the test.